Tags

Type your tag names separated by a space and hit enter

Amenorrhea and galactorrhea: results of therapy with 2-Brom-alpha-ergocryptine (CB-154).
Am J Obstet Gynecol. 1975 May 01; 122(1):85-9.AJ

Abstract

Administration of Brom-ergocryptine (CB-154) has a dramatic effect on breast secretion. Inhibition of lactation occurs within three to four weeks in women with amenorrhea and galactorrhea. Resumption of normal ovulatory function was documented by serum progesterone levels, as well as pregnancy, in three of four women attempting to conceive. Serum prolactin levels become normal following initiation of Brom-ergocryptine. Discontinuation of Brom-ergocryptine was found to result in a return of both inappropriate lactation and elevation of serum prolactin in this study. No deleterious side effects of Brom-ergocryptine have been found in any of the volunteers either clinically or on the basis of sequential laboratory studies.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1168997

Citation

Lloyd, S J., et al. "Amenorrhea and Galactorrhea: Results of Therapy With 2-Brom-alpha-ergocryptine (CB-154)." American Journal of Obstetrics and Gynecology, vol. 122, no. 1, 1975, pp. 85-9.
Lloyd SJ, Josimovich JB, Archer DF. Amenorrhea and galactorrhea: results of therapy with 2-Brom-alpha-ergocryptine (CB-154). Am J Obstet Gynecol. 1975;122(1):85-9.
Lloyd, S. J., Josimovich, J. B., & Archer, D. F. (1975). Amenorrhea and galactorrhea: results of therapy with 2-Brom-alpha-ergocryptine (CB-154). American Journal of Obstetrics and Gynecology, 122(1), 85-9.
Lloyd SJ, Josimovich JB, Archer DF. Amenorrhea and Galactorrhea: Results of Therapy With 2-Brom-alpha-ergocryptine (CB-154). Am J Obstet Gynecol. 1975 May 1;122(1):85-9. PubMed PMID: 1168997.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amenorrhea and galactorrhea: results of therapy with 2-Brom-alpha-ergocryptine (CB-154). AU - Lloyd,S J, AU - Josimovich,J B, AU - Archer,D F, PY - 1975/5/1/pubmed PY - 1975/5/1/medline PY - 1975/5/1/entrez SP - 85 EP - 9 JF - American journal of obstetrics and gynecology JO - Am J Obstet Gynecol VL - 122 IS - 1 N2 - Administration of Brom-ergocryptine (CB-154) has a dramatic effect on breast secretion. Inhibition of lactation occurs within three to four weeks in women with amenorrhea and galactorrhea. Resumption of normal ovulatory function was documented by serum progesterone levels, as well as pregnancy, in three of four women attempting to conceive. Serum prolactin levels become normal following initiation of Brom-ergocryptine. Discontinuation of Brom-ergocryptine was found to result in a return of both inappropriate lactation and elevation of serum prolactin in this study. No deleterious side effects of Brom-ergocryptine have been found in any of the volunteers either clinically or on the basis of sequential laboratory studies. SN - 0002-9378 UR - https://www.unboundmedicine.com/medline/citation/1168997/Amenorrhea_and_galactorrhea:_results_of_therapy_with_2_Brom_alpha_ergocryptine__CB_154__ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-9378(75)90618-3 DB - PRIME DP - Unbound Medicine ER -